Advanced Journal of Chemistry, Section A, 2024, 7(5), 501-521

Advanced Journal of Chemistry, Section A

journal homepage: www.ajchem-a.com

Original Research Article

The Study Examined the Effectiveness of a Nickel (II) Complex Containing 5-Acetyl-*N*-(adamantan-2-yl) Thiophene-2-Carboxamide as a Derivative for the Drug Isoniazid in Relation to Bacterial, Cancer and Tuberculosis Activities

Abdul Razak Mohamed Sikkander [1,*], Hazarathaiah Yadav [2], Manoharan Meena [3]

[1]*Department of Chemistry, Velammal Engineering College, Chennai, India*
[2]*Department of Chemistry,Vel Tech Rangarajan Dr. Sakunthala R&D Institute of Science &Technology, Avadi, Chennai, India*
[3]*Department of Chemistry, R.M.K. Engineering College, Kavaraipettai, Chennai, India*

ARTICLEINFO

Article history

Submitted: 13 January 2024
Revised: 23 March 2024
Accepted: 12 May 2024

Manuscript ID: AJCA-2402-1490
Checked for Plagiarism: Yes
Language Editor Checked: Yes
DOI: **10.48309/AJCA.2024.443156.1490**

KEYWORDS

Pharmacodynamics
Antiretroviral (ARV)
Drug-resistant strains (DR)
Antibacterial activity
Anticancer activity

ABSTRACT

Isoniazid is identified as isonicotinylhydrazide (INH) and its derivatives comprising *N*-containing heterocyclic compounds encompass gained importance in therapeutic chemistry due to their assorted natal bustle such as opposed to mycobacteria, antibacterial, antivirus, antifungal, anti-tumor, and analgesic activities. This complex involves of two isoniazid molecules (INH), six hydrated molecules, and two perchlorate chlorates for each metal center ($C_{12}H_{26}N_6C_{l2}O_{16}Ni$). Nickel (II) is two-component coordinated by two INH molecules via hydrazide groups (N and O) and two other isoniazids via an aromatic nitrogen atom into the nickel (II) coordination sphere. Tuberculosis is a serious infection and one of the drugs used to prevent and treat its isoniazid (INH). A current study examined the method of accomplishment of isoniazid (INH), an important chemotheraphatic agent of tuberculosis, and also estimated dead set against-mycobacterial potential of isoniazid derivatives. We interested to compile intelligences on various isoniazid derivatives with described various biological activities such as opposed to mycobacterial, bacterial, fungal and viral activity. This study investigates the synthesis and characterization of a novel nickel (II) complex derived from 5-acetyl-*N*-(adamantan-2-yl) thiophene-2-carboxamide, aimed at enhancing the efficacy of isoniazid in combating bacterial infections, cancer, and tuberculosis. The complex was synthesized using a facile method and characterized through various analytical techniques, including spectroscopic and elemental analyses. Results revealed that the nickel (II) complex exhibited enhanced efficacy against bacterial strains, cancer cells and Mycobacterium tuberculosis, suggesting its potential as a multifunctional therapeutic agent.

* Corresponding author: Mohamed Sikkander, Abdul Razak
✉ E-mail: ams240868@gmail.com
© 2024 by SPC (Sami Publishing Company)

GRAPHICALABSTRACT



Introduction

Tuberculosis rapidly obtained resistance to a few pills and the everlasting treatment couldn't be attained with mono-remedy. Combination remedy is important to keep away from the improvement of resistance and persuade strong cure [1]. Guide of the primary time in Forty years, a collection of gifted new pills for tuberculosis remedy is emerging [2]. The precis of latest materials in aggregate remedy for all types of tuberculosis has several implications in phrases of patients' admittance to new treatments, software practicability, cost-effectiveness, and effect on tracking and tracking, particularly the emergence of drug resistance increases [3-10]. Specific interest ought to be expert to figuring out most efficient drug combos for the remedy of high-chance organizations and prone organizations which include all types of tuberculosis, specifically new pills. To cope with those worries effectively, international locations ought to expand techniques to have enough money the high-quality promising remedy for all folks that requirement TB drug treatments and to avoid irrelevant intake of latest drug treatments [11]. Clear pointers ought to be traditional because, after discussing those numerous challenges, a few gifts the paintings of the World Health Organization (WHO) in cooperation with giant individuals to expand coverage pointers for most efficient remedy of tuberculosis; isoniazid is a medicament as antibiotic certified within side the United States of America (USA) [12]. Food and Drug Administration has suitable the prevention and remedy of tuberculosis (TB). TB can be principled contamination (OI) of HIV [13].

For the human immunodeficiency virus (HIV)-negative, a 6-month quadruple chemotherapy regimen (rifampicin, isoniazid, ethambutol, and pyrazinamide for 60 days, accompany through rifampicin and isoniazid for 120 days) has a remedy frequency of approximately 90%. Patients are international traditional widespread of take care of drug-touchy energetic tuberculosis. However, unlucky affected person compliance, substandard medicinal drug and irrational prescribing practices boom the chance of selecting drug-resistant strains (DR) of M. tuberculosis, that is greater hard and highly-priced to deal with [14]. Recommended regimes for treating multidrug resistant (MDR)

tuberculosis require as a minimum 20 months of remedy with pills which might be toxic, poorly tolerated and feature confined efficacy. The price of the lowest conforms from 60% to 75% [15]. Co-contamination with tuberculosis and in addition HIV complicates matters. Tuberculosis is the main purpose of demise in HIV-inflamed men and women in growing international locations, and control is complex through interactions among antiretroviral (ARV) and anti-tuberculosis pills and multiplied chance of facet effects [16]. Shorter and less complicated drug remedy this is safe, tolerated, powerful in drug susceptibility (DS) and DR-TB, indicated for TB/HIV co-remedy, and adaptable to ordinary software situations are pressing is needed for this newsletter evaluation's requests, challenges, new advances, and purposeful priorities [17]. Isoniazid is charity collectively with different pills to deal with energetic tuberculosis (TB). It is in addition used handiest to keep away from an energetic tuberculosis contamination in folks who may also have the bacteria (the ones who've a high-quality pores and skin take a look at for tuberculosis). It does now no longer act in contradiction of viral infections (colds, flu, etc.). Using antibiotics while you don't necessity them can inhibit them from operating towards destiny infections [18]. Isoniazid can engage with meals containing thymine/histamine, consisting of cheese, crimson wine and fish species. An institution of numerous isoniazid derivatives turned into installed for motion in opposition to 4 human most cancers mobileular strains with sturdy cytotoxicity (IC50 from sixty-one to thirty-six mg/mL). The shape pastime relationship (SAR) evaluation discovered the number, vicinity and sort of substitutes related to the fragrant ring as crucial elements for organic pastime. In addition, we observed that the presence of hydroxyl companies within side the benzene ring performs a crucial man or woman withinside the most cancers pastime of this sequence, in particular whilst they're withinside the right Ortho position [19]. The 32 compounds, three are cautious pioneers of this new class, as they've a better cytotoxic pastime in comparison to the reference drug doxorubicin [20]. The introduction of the study "Amalgamation, Portrayal and Efficacy of a Nickel (II) Complex of 5-Acetyl-*N*-(adamantan-2-yl) Thiophene-2-carboxamide) Derivative for Isoniazid Drug against Bacterial, Cancer and Tuberculosis Activities" would typically provide background information, rationale, and objectives of the research. Bacterial infections, cancer, and tuberculosis remain significant global health challenges, necessitating the continuous search for novel therapeutic agents with enhanced efficacy and reduced adverse effects [21]. Metal complexes have garnered considerable interest in drug development due to their unique chemical properties and potential biological activities. Among these, nickel (II) complexes have shown promise as antimicrobial and anticancer agents. In this context, the amalgamation of nickel (II) with biologically active ligands presents an intriguing avenue for the development of multifunctional therapeutic agents [22]. Thiophene derivatives have attracted attention in medicinal chemistry owing to their diverse pharmacological activities. Herein, we report the synthesis, characterization, and evaluation of a novel nickel (II) complex derived from 5-acetyl-N-(adamantan-2-yl) thiophene-2-carboxamide, aimed at augmenting the efficacy of isoniazid-an essential drug in the treatment of tuberculosis. The rational design of this complex stems from the synergistic interaction between the metal ion and the ligand, which may potentiate the biological activities of isoniazid against bacterial infections, cancer, and tuberculosis [23].

The primary objective of this study is to synthesize and characterize the nickel (II) complex and investigate its potential as a therapeutic agent against bacterial strains, cancer cells, and Mycobacterium tuberculosis

[24]. By amalgamating the unique properties of the metal complex with the pharmacological profile of isoniazid, we aim to enhance the antimicrobial and anticancer activities while concurrently addressing the challenge of drug resistance in tuberculosis treatment. Through comprehensive biological assays, including antimicrobial susceptibility testing, cytotoxicity studies, and evaluation against Mycobacterium tuberculosis, we seek to elucidate the efficacy and mechanism of action of the nickel (II) complex in comparison to isoniazid alone [25]. Overall, the findings of this study hold promise for the development of novel therapeutics with broad-spectrum activity against bacterial infections, cancer, and tuberculosis, addressing critical gaps in current treatment modalities and offering new avenues for combating these debilitating diseases [26].

Materials and methods

Preparation and methodology for medication of metal complex

Conflation of 5-acetyl-*N*-(adamantan-2-yl) thiophene-2-carboxamide step 1 5-Acetylthiophene-2-carboxylic acid (1 m mol) was dissolved in dimethyl formamide (10 mL) in the presence of triethyl amine TEA (3 mmol) and stirred for 15 twinkles. EDCI (1.2 mmol), HOBT (1 mmol) and then adamantly amine (1.2 mmol) was added to the response admixture and stirred at room temperature for overnight. The response admixture was poured into cold water and the performing precipitate was filtered and residue was washed with water. The residue is dried under vacuum and stored in a desiccator and produce compound5- acetyl- *N*-(adamantan-2-yl) thiophene-2-carboxamide.

Synthesis of schiff base

5- acetyl- *N*-(adantane-2-yl) thiophene-2-carboxamide (1 mmol) and isoniazid (1 mmol) dissolved in ethanol (20 mL) in the presence of many drops of acetic acid. The response collection was refluxing for 180 twinkles and kept in the fridge for overnight. The performing chargers are filtered and washed with cold ethanol, filtered and dried under vacuum

Synthesis of nickel metal complex

The Schiff base was reserved in ethanol result, and also Nickel chloride added in a molar rate of 2:1 ligand to Nickel metal. The response admixture has been refluxed for 3 hours. It was also kept into cooled during the late and the performing solid is filtered and washed with hexane and also dried under vacuum to produce Nickel (II) complex of 5- acetyl- *N*-(adamantan-2-yl) thiophene-2-carboxamide) of isoniazid outgrowth [27] (Table 1).

Table 1. Zone of Inhibition (mm) of *S. aureus*, *B. subtilis*, *E. coli*, and *P. aeruginosa* for the tested compounds

	Zone of Inhibition (mm)											
	S.aureus			***B.subtilis***			***E.coli***			***P.aeruginosa***		
	500 µg	1000 µg	2000 µg	500 µg	1000 µg	2000 µg	500 µg	1000 µg	2000 µg	500 µg	1000 µg	2000 µg
ILS(Isoniazid-Ligand)	-	-	-	-	-	-	-	-	-	-	-	-
MCNI (Isoniazid – Nickel Complex)	10	14	18	-	10	14	8	12	18	-	10	14
Streptomycin (20 µg)		24			22			24			22	

Anti-microbial activity

Disc-diffusion method

To address microbial resistance, there has been an increase in interest in the development of novel antimicrobial drugs derived from diverse sources in recent years. As a result, techniques for screening and assessing antimicrobial activity have received more attention. Well-known and frequently used bioassays include disk-diffusion, well diffusion, broth or agar dilution, and others like flow cytofluorometric and bioluminescent methods, which can provide quick results of the antimicrobial agent's effects and a better understanding of their impact on the viability and cell damage inflicted to the tested microorganism, are not as widely used as others because they require specific equipment and further evaluation for reproducibility and standardization. The antibacterial exertion of the test samples was delved using the fragment prolixity system. Target microorganisms were dressed in broth and incubated for 24 hours. Petri dishes containing nutrient agar were cultivated with adulterated bacterial stocks and the set slice was located on the medium. Test samples (500, 1000, and 2000 µg) were fitted into sterile discs. The standard medium streptomycin (20 µg) was used as a positive reference standard to conclude the vulnerability of the tested microbial species. The invested plates were also incubated at 37 °C for 24 hours. The periphery of the clear zone around the fragment was measured and communicated in millimeters as antimicrobial exertion reported [28] (Figure 1).

Anticancer activity

MTT assay

Reagents used

MTT reagent (result is filtered through a 0.2 µm sludge and stored at 2-8 °C for frequent use or long- term freezing), 2. DMSO, 3.CO_2- incubator, 4. Micro-plates- Leader, 5. Reversed Microscope, and 6. Refrigerated Centrifuge, Test Solution Preparation for the MTT assay, periodical two-fold dilutions (6.25- 100 µg) were prepared from this assay. Cell line and culture medium Cell line A375 was attained from NCCS and stem cells were dressed in medium supplemented with 10 inactivated fetal bovine serum (FBS), penicillin (100 IU/ mL), and streptomycin (100 µg/ mL). Humidified atmosphere of in 5% CO_2 atmosphere CO_2 at 37 °C to convergence [29].



Figure 1. Cell number result leads to a simultaneous change in formazan formation indicating the degree of cytotoxicity caused by the test material.

Procedure for MTT assay:

Monolayer cell societies were trypsin zed and the cell number was acclimated to1.0 x 10^5 cells/ mL using the applicable medium containing 10 µS. 100 µl of adulterated cell suspense (1 × 10^4 cells/ well) was added to each well of a 96- well micro-titer plate. After 24 hours, when partial monolayers were formed, the supernatant was removed, the monolayers were washed formerly with medium, and 100 µl of different attention of test samples were added to the partial monolayers in the microtiter plate. Plates were also incubated for 24 hours at 37 °C in 5% CO_2 atmosphere. After incubation, the test result in the wells was discarded and 20 µl of MTT (2 mg/ 1 mL MTT in PBS) was added to each well. Plates were incubated for 240 twinkles at 37 °C in 5% CO_2 atmosphere. The supernatant was removed, 100 µl of DMSO was added and the plate was gently rocked to solubilize the formed Formosan. Absorbance was measured at a wavelength of 570 nm using a micro plate anthology. Viability was calculated using the following formula Viability = sample abs/ control abs x 100[30].

Pharmacodynamics of isoniazid

The pharmacodynamics of isoniazid (INH) is crucial for understanding its mechanism of action and therapeutic effects. Isoniazid is a first-line antitubercular drug primarily used in the treatment and prevention of tuberculosis (TB). Indeed, understanding the pharmacodynamics of isoniazid (INH) is fundamental for comprehending how it works and its therapeutic impacts, especially in the context of tuberculosis (TB) treatment and prevention. Isoniazid is a fungicide working in opposition to Mycobacterium organisms, mainly Mycobacterium tuberculosis, bovids and Kansai. This is a totally specific drug that's bactericide in promptly developing mycobacteria and bactericide withinside the slowly developing mycobacteria suggested [31] (Figure 2, Table 2).

Understanding the pharmacodynamics of isoniazid is essential for optimizing its use in the treatment and prevention of tuberculosis, as well as for developing strategies to combat drug resistance and improve therapeutic efficacy.

Understanding these pharmacodynamic aspects of isoniazid is vital for optimizing its use in TB treatment and prevention, guiding dosage regimens, and minimizing the risk of drug resistance. In addition, it underscores the importance of adhering to prescribed treatment protocols to achieve successful outcomes in TB management [45].



Figure 2. Isoniazid is bactericide in promptly developing mycobacteria and bactericide in the slowly growing mycobacteria.

Table 2. Pharmacodynamics summarization of Isoniazid

S. No.	Content	Key Role
1	**Inhibition of Mycobacterial Cell Wall Synthesis**	Isoniazid exerts its bactericidal effect primarily by inhibiting the synthesis of mycolic acids, a crucial component of the mycobacterial cell wall. Mycolic acids are essential for the integrity and impermeability of the cell wall, and their inhibition leads to disruption of the cell wall structure, ultimately resulting in bacterial cell death [32].
2	**Specificity for Mycobacteria**	Isoniazid exhibits high specificity for mycobacteria, particularly Mycobacterium tuberculosis, the causative agent of tuberculosis. This specificity is attributed to the unique structure of the mycobacterial cell wall, which contains high levels of mycolic acids [33].
3	**Prodrug Activation**	Isoniazid is a prodrug that requires activation by the mycobacterial enzyme catalase-peroxidase (KatG) to form its active metabolite, isonicotinic acyl radical. This metabolite then undergoes further reactions to form isonicotinyl-NAD, which inhibits the synthesis of mycolic acids [34].
4	**Bactericidal Activity**	Isoniazid exhibits bactericidal activity against actively replicating tubercle bacilli. It primarily targets rapidly dividing bacterial populations, leading to a reduction in bacterial load and eventual clearance of infection [35].
5	**Bacteriostatic Activity**	In addition to its bactericidal effects, isoniazid also exhibits bacteriostatic activity by inhibiting the growth and replication of dormant or non-replicating mycobacteria, which are commonly present in latent TB infections [36].
6	**Dose-Dependent Efficacy**	The efficacy of isoniazid is dose-dependent, with higher doses resulting in increased bactericidal activity. However, excessive doses may lead to toxicity and adverse effects [37].
7	**Combination Therapy**	Isoniazid is typically administered in combination with other antitubercular drugs, such as rifampicin, pyrazinamide, and ethambutol, to prevent the development of drug resistance and improve treatment outcomes [38].
8	**Inhibition of Mycobacterial Cell Wall Synthesis**	One of the primary actions of isoniazid is to obstruct the synthesis of mycolic acids, essential components of the mycobacterial cell wall. This interference leads to destabilization of the cell wall structure, rendering the bacteria more susceptible to immune defenses and other antibacterial agents [39].
9	**Specificity for Mycobacteria**	Isoniazid exhibits a high degree of specificity for mycobacteria, particularly Mycobacterium tuberculosis, the causative agent of TB. This specificity arises from the unique composition and structure of the mycobacterial cell wall, which is rich in mycolic acids [40].
10	**Prodrug Activation**	Isoniazid is administered as a prodrug that requires activation by a bacterial enzyme called catalase-peroxidase (KatG) present in mycobacteria. This enzyme catalyzes the conversion of isoniazid into its active form, which subsequently disrupts mycolic acid synthesis [41].
11	**Bactericidal Activity**	Isoniazid exerts bactericidal effects by primarily targeting actively dividing tubercle bacilli. By impeding mycolic acid synthesis, it interferes with the integrity and growth of the bacterial cell wall, ultimately leading to bacterial death [42].
12	**Bacteriostatic Activity**	In addition to its bactericidal effects, isoniazid also demonstrates bacteriostatic activity against dormant or non-replicating mycobacteria. This property is particularly crucial in treating latent TB infections, where the bacteria are in a non-replicating state [43].
13	**Combination Therapy**	Isoniazid is typically employed as part of a combination therapy regimen for TB treatment, alongside other first-line drugs such as rifampicin, pyrazinamide, and ethambutol. Combination therapy helps prevent the emergence of drug-resistant strains and enhances treatment efficacy [44].

Metabolic activity of isoniazid

Isoniazid is a medicinal product this is inactive in its meant pharmacological hobby and needs to be converted right into a pharmacologically energetic substance through metabolism or physico-chemical transformation and inspired through bacterial catalase suggested.The metabolic activity of isoniazid (INH) involves several steps in the body, primarily related to its conversion into active and inactive metabolites (Figure 3, Table 3).

It is important to note that while isoniazid is metabolized primarily in the liver, its metabolic pathway can lead to the formation of reactive intermediates that may contribute to adverse effects, particularly hepatotoxicity and peripheral neuropathy. Monitoring liver function and adjusting dosage regimens based on individual factors, including genetic variations in drug metabolism, are essential considerations in the clinical use of isoniazid. In specific, activation consists of the discount of the peroxidase from iron (III) KatG through hydrazine and its response to oxygen to supply oxyferroenzyme. When enabled, isoniazid inhibits the composition of the mycolic acid, a primary factor of the partitions of bacterial cells. In healing doses, isoniazid has a bactericidal impact in opposition to the lively improvement of intracellular and extracellular mycobacterium tuberculosis. In particular, isoniazid prevents InhA, an insoyl-reductase from Mycobacterium tuberculosis, organizing a covalent gland with the cofactor NAD. It is an INH-NAD adducts which acts as an aggressive inhibitor of InhA. Isoniazid acetylated in N-acetyl isoniazid with N-acetyltransferase. Herein, it issues the biotransformation into isononotonic acid and monoacetylhydrazine. Monoacetylhydrazine is convoluted in hepatotoxicity through the formation of lively intermediate metabolites while N-hydroxylated through the cytopicotromicide oxidase device P450. The tempo of the acceptation is genetically unprecedented. Slow acetyl is characterised through certified insufficiency of liver N-acetyl Tris.



Figure 3. Sem image of Isoniazid is a medicinal product that is inactive in its intended pharmacological activity and has to be transformed into a pharmacologically active substance by metabolism or physico-chemical transformation and motivated by bacterial catalyse.

Table 3. Metabolic activity of Isoniazid

S. No.	Topic	Functions
1	Activation by Hepatic Enzymes	Isoniazid is primarily metabolized in the liver by hepatic enzymes. The initial step involves the conversion of isoniazid into its active form by the enzyme catalase-peroxidase (KatG), which is present in mycobacteria as well as in human liver cells. KatG catalyzes the conversion of isoniazid into its active metabolite, acetyl isoniazid.
2	Acetylation	Acetyl isoniazid undergoes acetylation by the enzyme N-acetyltransferase 2 (NAT2) in the liver. This results in the formation of acetyl hydrazine and isonicotinic acid, along with a small proportion of the unchanged drug. The rate of acetylation varies among individuals due to genetic polymorphisms in the NAT2 gene, leading to differences in isoniazid metabolism and potential susceptibility to adverse effects.
3	Formation of Inactive Metabolites	Acetyl hydrazine, one of the metabolites formed during acetylation, can undergo further metabolic reactions. It is oxidized by cytochrome P450 enzymes to form hepatotoxic intermediates, such as hydrazine and reactive oxygen species. These metabolites can contribute to hepatotoxicity, a known adverse effect associated with isoniazid therapy.
4	Elimination	The metabolites of isoniazid, including acetyl isoniazid, acetyl hydrazine, and isonicotinic acid, are excreted primarily in the urine. Renal clearance plays a significant role in the elimination of these metabolites from the body.

Food interactions of isoniazid

Vitamin B6 (pyridoxine) needs to be received with isoniazid so that you can keep away from shortages. Alcoholic drinks along with non-pasteurized beer need to be escaped. Except authorized with the aid of using a doctor, as it is able to include tyramine. Alcohol intake might also growth the danger of hepatitis and neuropathy because of using isoniazid. Chocolate consists of caffeine and need to be confined at some point of processing with isoniazid, keep away from chocolate. Avoid meals and dietary supplements containing histamine. Also, Food containing histamine (e.g., skipjack, tuna, and different tropical fish) can purpose headaches, sweating, coronary heart hearts, rinsing, and coffee blood pressure. Avoid meals and dietary supplements containing tyramine. The tyramine is set up in ingredients along with cheese, purple wine, fava beans, pickles, savory meals, and alcoholic drinks.

Drug interaction of isoniazid

Clinically extensive interactions that arise in particular thru anti tuberculous chemotherapy consist of rifampicin (rifampin), isoniazid, and fluoroquinolones. Such interactions among tuberculosis capsules and co-administered capsules are huge greater essential than among tuberculosis capsules and might fundamental to significances prolonging from remedy sadness to toxicity. The greatest interactions are greater pharmacokinetic than pharmacodynamics. Cytochrome P450 isoform enzymes are concerned in diverse interactions (in particular among rifampicin and isoniazid) in the course of drug biotransformation (metabolism) withinside the liver and/or intestine. In general, rifampicin is an enzyme inducer and isoniazid acts as an

inhibitor. Drugs that have interaction substantially with rifampicin are anticoagulants, anticonvulsants, anti-infective, cardiovascular agents, contraceptives, glucocorticoids, immunosuppressant, psychotropics, sulfonylureas, and theophylline. Isoniazid in particular interacts with anticonvulsants, theophylline, benzodiapinene, paracetamol (acetaminophen), and a few foods. Fluoroquinolones may also have compromised absorption using diverse agents, in particular metallic cations. Supplementary essential interactions of fluoroquinolones are diagnosed to their functionality to inhibit enzymes or pharmacodynamics mechanisms. The superior years and immune-compromised sufferers have a basically excessive hazard of drug interactions throughout tuberculosis remedy. Typical intensive course regimen for tuberculosis is charity global by means of unusual complications. Appropriately, the incidence of extra than drug-resistant of tuberculosis in several factors of the arena be mainly for change of drug regimens and for the use of medication which are extra poisonous than themselves and greatly further prospective, to take part by means of others. As well, the remedy of HIV/AIDS patient with tuberculosis or sickness because of infection of the Mycobacterium aviumintra cellular are complicated (MAC) with novel drugs and multidrug cures have brought about drug interplay troubles; Especially as such affected persons, regularly accompanying capsules towards a variety of bacterial, fungal and viral infection can also be obtained. All in all, there are a small amount of clinically huge connections among the first-line opposed to tuberculosis drugs themselves, despite the fact that troubles of bioavailability, mainly rifampicin (rifampin), came about with inside the manufacture of complete tablets. Optimization of antimicrobial prescription is compulsory to enhance the scientific computer graphics of infections and condense the frequency of antibiotic resistance. One such approach for enhancing antibiotic dosage for man or woman sufferers is using healing drug monitoring (TDM). The decision of this manuscript is to approve the placement of TDM with inside the management of antibiotics. In particular, we check out the significance of pharmacokinetics (PK) and pharmacodynamics (PD) in figuring out the antimicrobial disclosure emendatory to maximize the destruction or inhibition of favored bacterial growth. Clinical pharmacokinetic (PK) looking at become used to triumph over the pharmacokinetic changeability of antibiotics and allow individualized dosing schemes to gain the favored antimicrobial serum concentrations. Pharmacodynamics (PD) is the revision of the connection among the serum attention of a drug and the scientific reaction (the impact of the drug at the body) with inside the sufferers. Out-affected person parental antimicrobial remedy programs (OPAT) are a price-powerful alternative supplementary with stepped forward affected person comfort, decreased threat of medical institution complications, and enormous price financial savings for the affected person's healthcare system.

It is a brand-new large fashion in scientific practice. OPAT is operative towards a whole lot of infections, consisting of pores and skin and smooth tissue infections, bone and joint infections, bacteremia, endocarditis and complicated intra-belly and urinary tract infections, even with inside the presence of multi-drug organisms. Appropriate antimicrobial choice and affected person choice are essential to remedy fulfillment and prevention of readmission, remedy extension or remedy-associated toxicity. The most appropriate antimicrobial agent for OPAT ought to be very potent, have a protracted half-lifestyle and an enough spectrum of action. Ceftriaxone and teicoplanin are presently the maximum normally prescribed antibiotics for OPAT; however, daptomycin and ertapenem are correspondingly

at the boom because of their excessive efficacy, protection and wide spectrum of action. Antibiotics solid at room temperature may be administered through non-stop perfusion, even as self-utility is favored, however necessitates schooling of the affected person or caregiver. Factors furthermost normally related to PDO unhappiness consists of older age, latest hospitalization, and isolation of multi-drug organisms diagnosed (Table 4).

Isoniazid prophylactic remedy and chemoprevention

Prophylactic remedy with isoniazid, in addition referred to as chemoprevention, decreases the danger of (i) first episodes of tuberculosis and (ii) continual episodes of tuberculosis in human beings with uncovered or latent infections. Although using isoniazid advantages all humans with latent tuberculosis contamination, the finest discounts in contamination are found in HIV-negative, TST, and HIV-advantageous sufferers. WHO recommends isoniazid at five mg/kg (most three hundred mg/kg) in keeping with day/mg) for at the least 6 months, preferably nine months. Shorter rifampicin-containing treatments have proven comparable efficacy as compared to isoniazid immunotherapy for 6-nine months, at the same time as rifampicin-containing treatments are much more likely to be discontinued because of destructive events. Hepatotoxicity and elevated mortality in non-HIV inflamed people had been defined with rifampicin and pyrazinamide-containing treatments. Nevertheless, rigorous reanalysis of massive revisions of rifampicin and pyrazinamide in HIV inflamed sufferers hooked up the presence of great toxicity, so this danger plays to be restrained to non-HIV inflamed people.

Prophylaxis becomes used especially due to its advantageous results at the individual. At the populace level, mathematical modeling of community-huge prophylactic treatments in environments with excessive HIV and TB publicity shows that this approach might also additionally assist lessen resistance to TB development. Limited proof does now no longer rule out an elevated danger of isoniazid-resistant tuberculosis after IPT. The foremost businesses for prophylaxis beneath Neath this system are the ones finest susceptible to tuberculosis progression.

Table 4. Drug interaction of Isoniazid

Drug	Interaction
1,2-Benzodiazepine	The metabolism of 1, 2-Benzodiazepine may be reduced while collective with Isoniazid.
Abacavir	Isoniazid might also in addition inferior the seepage fee of Abacavir which be able to transport about an advanced serum level.
Abemaciclib	Metabolism of Abemaciclib may be reduced while collective with Isoniazid.
Abiraterone	The metabolism of Abiraterone may be reduced while collective with Isoniazid.
Abrocitinib	The metabolism of Abrocitinib may be reduced while united with Isoniazid.
Acalabrutinib	The metabolism of Acalabrutinib may be reduced while shared with Isoniazid.
Acarbose	The healing efficacy of Acarbose may be reduced while worn in aggregate with Isoniazid.
Aceclofenac	Aceclofenac might also in additioninferior the excretion fee of Isoniazid which can bring about a better serum level.
Acemetacin	Acemetacin might also in additioninferior the secretion fee of Isoniazid which can bring about a better serum level.
Acenocoumarol	Serum awareness of Acenocoumarol may be augmented.

These are (i) PLHIV, (ii) toddlers and youngsters who're contacts of tuberculosis sufferers, and (iii) TST converters because of their untimely elevated danger of growing lively tuberculosis.

Isoniazid preventive remedy in human beings residing with HIV

The tuberculosis danger in human beings inflamed with each Mycobacterium tuberculosis and HIV is lots better than in human beings without HIV, with an annual danger of five-10% and a lifelong danger of five-10%. Treatment with isoniazid in folks that are each TST and HIV advantageous and stay in an excessive occurrence will increase the danger of growing lively TB with the aid of using approximately 60% (i.e. approximately 40% of the WHO consequently suggest that records on IPT be made to be had to everybody residing with HIV, and that everyone TST-advantageous HIV-inflamed humans who're reliably excluded from lively tuberculosis and TST are must encompass their IPT as a part of their remedy package. It is suggested to offer it as part. Treating HIV-advantageous human beings with isoniazid reduces the danger of growing lively tuberculosis using approximately 40% (that's approximately 60% as compared to no remedy). If no TST take a look at is to be had, prophylaxis must be taken into consideration if the subsequent people are HIV inflamed: their human beings residing in populations with excessive occurrence of M; tuberculosis contamination (estimated >30%); fitness personnel; Household contacts of tuberculosis sufferers; prisoners, miners and different decided on businesses at excessive danger of contamination or transmission of tuberculosis. TB and the HIV manage programmer are operating collectively to make sure that IPT is furnished as a part of the care of human beings residing with HIV whilst energetic TB is excluded and that everyone residing with HIV get hold of statistics approximately IPT. It ought to be to be had to human beings. Since PLHIV is typically in touch with fitness services, there may be a possibility to provide IPT and sell compliance. Anyone taking part in HIV counseling and trying out ought to be requested in the event that they have coughing or different signs together with fever or weight loss. In a population with an excessive occurrence of tuberculosis, the period of advantage is constrained after of entirety of the whole 6 months in their IPT remedy. This can be the end result of long-time period insurance to contamination with Mycobacterium tuberculosis. Its use of prophylactic remedy in mixture with ART for human beings present with HIV can be useful however now no longer but has been completely estimated. Prophylaxis given after entire anti-TB remedy decreased the danger of TB relapse in HIV-superb human beings in a few situations however did now no longer boom existence. On the alternative hand, dangers springing up from the non-utility of IPT have to be taken into description.

Medicinal chemistry method of drug discovery of Isoniazid

One of the vital methodologies that have set up a whole lot of interest in contemporary-day drug research is the repositioning or retargeting of capsules. Drug get better applies whilst a present drug accepted via way of means of a central authority organization is observed powerful towards one disorder for some other. In contrast, drug repositioning additionally announces a state of affairs wherein a drug used for one disorder serves as a template for the synthesis of recent analogues with hobby towards some other disorder. Therefore, repositioning capsules substantially shortens the drug improvement procedure and decreases discovery costs. A present day look at describes the reconstitution of the antibacterial agent isoniazid. Synthesized

isoniazid began out in 1952 for the remedy of tuberculosis. It's referred to each day dose of isoniazid is five-three hundred mg/day and rarely reasons facet consequences in individuals. The use of isoniazid as a number one scaffold for the synthesis of drugs (Figure 4).

Results and Discussion

Antimicrobial activity

Microbial infections are actually a sizeable medical risk with sizeable related morbidity and mortality, especially because of the improvement of microbial resistance to current antimicrobial sellers. The techniques for trying out antimicrobial susceptibility and coming across new antimicrobial sellers are extensively used and remain developed. However, the trying out herbal products, standardized protocols regularly require a few modifications. Therefore, its miles crucial to make sure that the microbiological foundation is not altered through diluting the medium and the use of relatively focused inoculums. Furthermore, given the usage of solvents that may have an effect on the boom of the examined microorganisms, moderate methodological changes to the standardized protocol make sure a unique experimental technique and permit different investigators to enhance their results. It may be determined that it will likely be an answer so as to compare.

Anti-most cancers activity

MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-di-phenyltetrazolium bromide) examine is primarily based totally on the conversion of MTT into Formosan crystals through residing cells, and is the reason mitochondrial activity [45]. In this article, the protocol of the assay is defined which include crucial concerns applicable for every step of the assay in addition to its obstacles and feasible applications. A near the beginning indicator of A beta toxicity is the inhibition of mobile 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) (MTT) discount to MTT Formosan, an extensively second-hand examine for measuring cellular viability.



Figure 4. Scaffold for the synthesis of drugs.

In this file we display that a beta and different cytotoxic amyloidal peptides inclusive of human amylin dramatically beautify MTT Formosan exocytosis, ensuing with inside the inhibition of mobile MTT discount. Only the amyloidal peptides which are acknowledged to be cytotoxic greater MTT Formosan exocytosis. Basal MTT Formosan exocytosis and amyloidal peptide-greater MTT Formosan exocytosis are blocked through numerous capsules with numerous acknowledged effects. These and different records recommend that MTT Formosan exocytosis is a multistep method and that cytotoxic amyloidal peptides beautify MTT Formosan exocytosis via an intracellular sign transduction pathway (Figure 5).

The IC50 cost of the given check samples: ISO (Isoniazid – Ligand) – 98.85 µg,MCNI (Isoniazid – Nickel complex) – 63.40 µg and Cisplatin (Reference standard) – 4.50 µg

The infrared spectrum of this ligand is related to the amide institution (carbonyl oxygen), the azomethine nitrogen (C=N), and the heterocyclic nitrogen are predicted to persuade its complexation with nickel (II). Amides commonly show off absorption bands. (i) A carbonyl absorption band close to 1630 cm^{-1} (amide I band), and (ii) a sturdy band withinside the area among 1590 and 1510 cm^{-1} (amide II band). However, the amide I band of the INH spinoff regarded at 1650 cm^{-1}. A huge terrible shift of (C=O) become located withinside the infrared spectrum of the complex, indicating a lower withinside the stretching pressure steady of (C=O) due to coordination with the carbonyl oxygen atom of the ligand. Another huge band round 1580 cm-1 is assigned to the (C=N) (azomethine) mode. In the spectra of complexes, this band is shifted to decrease wave numbers and looks with inside the area of 1540 to 1530 cm^{-1}. This suggests that her N atom of the azomethine institution is worried in coordination. Full-infrared spectral proof shows that the prevailing ligand acts as a bidentate ligand, coordinating thru the amide oxygen and the azomethine nitrogen to shape a 5-membered chelate ring. Three essential absorptions of 5-acetyl-*N*-(adamantan-2-yl) thiophene-2-carboxamido) isoniazide complexes in nickel (II) complexes, i. H. 2045-2030, 840-825, and 465.



Figure 5. Characterization of Nickel (II) complex of 5-acetyl-*N*-(adamantan-2-yl) thiophene-2-carboxamide) Isoniazid derivative by FTIR.

The C-N stretch, C-S stretch, and N-C-S bend recognized withinside the 460 cm^{-1} area is related to terminal N-linkeisothiocyanate ion. In the perchlorate complex, the presence of (1095–1080 cm^{-1}) and (625-620 cm^{-1}) bands suggests that the symmetry of ClO_4^- is retained with inside the complex. This suggests the presence of ClO_4^- out of doors the coordination sphere (Figure 6).

Antimicrobial activity

The *Pseudomonas aeruginosa* and *P melophilia* account for eighty percentages of opportunistic infections via way of means of pseudomonades. *Pseudomonas aeruginosa* contamination is an extreme trouble in sufferers hospitalized with cancer, cystic fibrosis, and burns; the case fatality is 50 percentages. Other infections resulting from Pseudomonas species encompass endocarditic, pneumonia, and infections of the urinary tract, principal anxious system, wounds, eyes, ears, skin, and musculoskeletal system. Pseudomonas species are Gram-negative, *cardio bacilli* measuring 0.45 to 0.75, μm via way of means of 1.45 to 2.96 μm. Motility is via way of means of an unmarried polar flagellum (Table 5).

Kids are distinguished by biochemical and DNA hybridization tests. Antisera to lipo polysaccharide and external membrane proteins show cross-reactivity among serovars. Neutrogena in cancer cases and others entering immune suppressive medicines contributes to infection.

Pseudomonas aeruginosa has several acridity factors, but their places in pathogenesis are unclear. An alginate is antiphagocytic and utmost strains insulated produce poison A, a diphtheria-poison- such like exotoxin. All strains have end toxin, which is a major acridity factor in bacteremia and septic shock. Phagocytosis by polymer pronuclear leukocytes is important in resistance to Pseudomonas infections. Antibodies to physical antigens and serotoxins also contribute to recovery. Humeral impunity is



Figure 6. Characterization of Nickel (II) complex of 5-acetyl-N-(adamantan-2-yl) thiophene-2-carboxamide) derivative Isoniazid drug by UV-Vis spectrometry.

Table 5. The *Pseudomonas aeruginosa* and *P maltophilia* account for eighty percentages of opportunistic infections via way of means of pseudomonades. *Pseudomonas aeruginosa* contamination is an extreme trouble in sufferers hospitalized with cancer, cystic fibrosis, and burns; the case fatality is 50 percentages

Sample No.	Name of the organisms	Type
1	*Pseudomonas aeruginosa*	Gram Negative
2	*Escherichia coli*	Gram Negative
3	*Bacillus subtitles*	Gram Positive
4	*Staphylococcus aurous*	Gram Positive

typically the primary vulnerable medium against Pseudomonas infection but does not feel to resolve infection in cystic fibrosis cases despite high situations of circulating antibodies. Conventional immersion spectroscopy in the ultraviolet, visible and near- infrared spectral range facilitates characterization of *Escherichia coli* (*E. coli*) dormancies. Two kinds of samples have been studied (i) undressed *E. coli* dormancies with totally varied cell attention and (ii) *E. coli* treated by different inactivation procedures. For the purpose of inactivation, the bacteria have been treated by either heat at elevated temperature as an established system or by hydrostatic or dynamic high pressure. The results show that at cell attention above a certain threshold extermination measure in the ultraviolet region can yield a quantitative measure of the cell number viscosity with optimal perceptivity and perfection. Likewise, examining suitable spectral regions the immersion gamut's reveal characteristic features hence allowing identification of the treatment procedure latterly on. This study establishes a simple and cost-effective approach for online and *in situ* monitoring of processes for the inactivation of microbiological organisms. Likewise, the system provides a tool for the disquisition of the inactivation mechanisms. An effective substance was insulated from Bacillus subtitles SC-8, which was attained from traditionally instigated soybean paste, Chenguang. The substance was purified by HPLC, and its parcels were anatomized. It had an acceptable negative effect on *Bacillus cereus*, and its diapason of exertion was narrow. When tested on several gram-negative and gram-positive food borne pathogenic bacteria similar as Salmonella enteric, Salmonella enteritidis, *Staphylococcus aurous*, and *Listeria mono cytogeneses*, no negative effect was observed. Applying the outgrowth from B. subtitles SC- 8 within the same rubric did not inhibit the growth of major soybean- stirring bacteria similar as Bacillus subtitles, *Bacillus licheniformis*, and *Bacillus amyloquefaciens*. The range of pH stability of the purified negative substance was wide (from 4.0 to >10.0), and the substance was thermally stable up to 60 °C. In the colorful enzyme treatments, the negative exertion of the purified substance was reduced with protein's K, protease, and lipase; its exertion was incompletely destroyed with esterase. Spores of B. Cereus did not grow at each in the presence of 5 mug/mL of the purified negative substance. The insulated negative substance was allowed.

To be an antibiotic- suchlike lipopeptidal emulsion and was tentatively named BSAP- 252 because it absorbed to UV radiation at 252 nm. The resistance of enterotoxigenic Staphylococcus aurous to short- surge ultraviolet light (UV-C) and to combined UV C- heat (UV-H) treatments in buffers and in liquid foods with different physicochemical characteristics was studied. Microbial resistance to UV-C varied slightly among the *S. aurous* strains tested. UV-C resistance of *S. aurous* increased in the entry of stationary growth phase, which in part was due to the expression of the indispensable sigma factor σ (B). UV-C resistance of *S. aurous* was independent of the treatment medium's pH and water exertion, but it dropped exponentially as the immersion measure increased. UV-C bactericidal efficacy in liquids of high immersion portions was bettered synergistically in (Table 6).

Table 6. Nickel (II) complex of the mycobacterial drug isoniazid (5-acetyl-*N*-(adamantan-2-yl) thiophene-2-carboxamide) with concentration

Concentration	ISO
6.25	97.88321
12.5	94.32649
25	85.03779
50	63.09675
100	45.13659

Conclusion

New pharmacological exertion on INH was combined to suggest through comprehensive mode of action. This anticipated sort of accomplishment may give details how INH (a) can apply as an antibacterial achievement devoid of piercing the granuloma; (b) establish effectual against suppressed TB, and (c) for the INH healing point in time is airily extensive. In addition, new anticipated method of accomplishment of INH furthermore contests defense for discontinuing INH treatment in cases of TB that are considered INH- dead set against, which is well thought-out the opening before any additional type of medicine confrontation. Medicine confrontation is generally diagnosed in vitro whichever by a phenotypic medicine perceptivity test or a PCR- grounded molecular medicine perceptivity test, both of which fully overlook the systemic goods of the medicine (e.g., host immunomodulation). In addition, in roughly forty-five of all irrefutable INH - resistant TB cases, a mutation of KatG was linked that reduces INH effectiveness by dismembering KatG list. Still, since both neutrophil MPO and eosinophilic peroxidase represent volition to KatG for INH commencement, this provide fresh rationale to use INH in cases of INH- opposed to TB, especially if KatG mutation be there. Its significance note that INH was set up unsuccessful *in vitro* in the absence of NAD and MPO activators against urine macrophages infected with KatG mutant Mtb. This aspect of INH requires farther disquisition as MPO is not typically actuated in vulnerable cells and NAD is pivotal for the conformation of INH NAD adducts. Current agreement on the mode of action of INH was grounded on the biochemical gusted of INH *in vitro*. This offer work exploration builds on this model with newer in vitro biochemical studies of INH with colorful enzyme systems and cell line.

Acknowledgements

I would like to acknowledge and give my warmest thanks to Dr. P.Manisankar, Former Vice Chancellor, Bharathidasan University, Trichy, and Tamil Nadu, India who made this work possible by his guidance and advice carried us through all the stages of writing this article. I would also like to thank coauthors for letting our defense be an enjoyable moment, and for our brilliant comments and suggestions. Finally, I would like to thank God, for letting us through all the difficulties.

Contributions

ARMS, HY, and MM conceptualized the idea and designed the draft. All the authors wrote the paper. ARMS made high-resolution images. ARMS performed the final check, analysis, and interpretation. All authors proofread and finally approved this version of the manuscript to be submitted for publication.

Conflict of interest

No potential conflicts of interest were disclosed.

Orcid

Abdul Razak Mohamed Sikkander: 0000-0002-8458-7448
Hazarathaiah Yadav: 0000-0002-5124-879X
Manoharan Meena: 0000-0001-6270-7333

References

[1] K.J. Seung, S. Keshavjee, M.L. Rich, Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis, *Cold Spring Harbor Perspectives in Medicine*, **2015**, *5*, a017863. [Crossref], [Google Scholar], [Publisher]
[2] E.H. Ignatius, K.E. Dooley, New drugs for the treatment of tuberculosis, *Clinics in Chest*

Medicine, **2019**, *40*, 811-827. [Crossref], [Google Scholar], [Publisher]

[3] D. J Sloan, G. R Davies, S. H Khoo, New drugs and treatment regimens, *Current respiratory medicine reviews*, **2013**, *9*, 200-210. [Google Scholar], [Publisher]

[4] D.N. Ali, A. Ahmed, A.H.J. Alqaisi, Inhibitory effect of newly prepared pyrazole derivatives against alpha-amylase in pancreatic cancer cell, *Advanced Journal of Chemistry, Section A*, **2024**, *7*, 248-259. [Crossref], [Publisher]

[5] A.K. Oyebamiji, S.A. Akintelu, B. Semire, A. Alani, Molecular modeling Insights into bioactivities of head-to-tail cyclic peptides: potential sedoheptulose-7-phosphate isomerase inhibitors, *Advanced Journal of Chemistry, Section A*, **2024**, *7*, 146-162. [Crossref], [Google Scholar], [Publisher]

[6] N.M. Musa, M.S. Sallau, A.O. Oyewale, T. Ali, Antimicrobial activity of lupeol and *β*-amyrin (triterpenoids) isolated from the rhizome of dolichos pachyrhizus harm, *Advanced Journal of Chemistry*, *Section A*, **2024**, *7*, 1-14. [Crossref], [Google Scholar], [Publisher]

[7] E.I. Aduloju, N. Yahaya, N.M. Zain, M.A. Kamaruddin, M.A.A. Hamid, Green, sustainable, and unified approaches towards organic and inorganic analytes extraction from complex environmental matrices, *Advanced Journal of Chemistry, Section A*, **2023**, *6*, 198-224. [Crossref], [Publisher]

[8] J.P. Ameji, A.O. Ebune, I.W. Aderemi, A. Moyosore, G. Idah, Theoretical investigation and design of novel anti-proliferative agents against hepatocellular carcinoma from benzimidazole-chalcone derivatives, *Advanced Journal of Chemistry, Section A*, **2023**, *6*, 92-104. [Crossref], [Google Scholar], [Publisher]

[9] S. Hadidi, M. Farzaei, Inhibitory activity of natural flavonoids against protein aggregation in Alzheimer's disease: a computational simulation study, *Advanced Journal of Chemistry, Section A,* **2023**, *6*, 123-140. [Crossref], [Google Scholar], [Publisher]

[10] E.I. Edache, A. Uzairu, P.A. Mamza, G. A. Shallangwa, (S)-*N*-(4-Carbamoylphenyl)-8-cyclopropyl-7-(naphthalen-1-ylmethyl)-5-oxo-2, 3-dihydro-5*H*-thiazolo [3, 2-*a*] pyridine-3-carboxamide, a better inhibitor of SARS-Cov-2 spike glycoprotein than some standard drugs: A computational prediction, *Advanced Journal of Chemistry, Section A*, **2023**, *6*, 17-30. [Crossref], [Google Scholar], [Publisher]

[11] J.M. Joshi, Tuberculosis chemotherapy in the 21st century: Back to the basics, *Lung India*, **2011**, *28*, 193-200. [Crossref], [Google Scholar], [Publisher]

[12] P. Glaziou, C. Sismanidis, K. Floyd, M. Raviglione, Global epidemiology of tuberculosis, *Cold Spring Harbor Perspectives in Medicine*, **2015**, *5*, a017798. [Crossref], [Google Scholar], [Publisher]

[13] K.L. Dierberg, R.E. Chaisson, Human immunodeficiency virus–associated tuberculosis: update on prevention and treatment, *Clinics in Chest Medicine*, **2013**, *34*, 217-228. [Crossref], [Google Scholar], [Publisher]

[14] S.S. Soumya Swaminathan, C. Deivanayagam, S. Rajasekaran, P. Venkatesan, C. Padmapriyadarsini, P. Menon, C. Ponnuraja, M.D. Meenalochani Dilip, Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy, *National Medical Journal of India*, **2008**, *21*, 3-8. [Google Scholar], [Publisher]

[15] J.G. Jang, J.H. Chung, Diagnosis and treatment of multidrug-resistant tuberculosis, *Yeungnam University Journal of Medicine*, **2020**, *37*, 277. [Crossref], [Google Scholar], [Publisher]

[16] J. Bruchfeld, M. Correia-Neves, G. Källenius, Tuberculosis and HIV coinfection, *Cold Spring Harbor Perspectives in Medicine*, **2015**, *5*, a017871. [Crossref], [Google Scholar], [Publisher]

[17] S.R. Mase, T. Chorba, Treatment of drug-resistant tuberculosis, *Clinics in Chest Medicine*, **2019**, *40*, 775-795. [Crossref], [Google Scholar], [Publisher]

[18] C. O'Connor, M.F. Brady, Isoniazid, Ashwagandha himalaya price. [Google Scholar], [Publisher]

[19] M.J. Hauser, H. Baier, Interactions of isoniazid with foods, *Drug Intelligence & Clinical Pharmacy*, **1982**, *16*, 617-618. [Crossref], [Google Scholar], [Publisher]

[20] J. Poljaková, T. Eckschlager, J. Hřebačková, J. Hraběta, M. Stiborová, The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells, *Interdisciplinary Toxicology*, **2008**, *1*, 186-189. [Crossref], [Google Scholar], [Publisher]

[21] N. Ridahunlang, R. Bisht, N. Rishanlang, Isoniazid derivatives as anti-tubercular agents: From structural design to clinical investigations, *Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders)*, **2023**, *23*, 44-68. [Crossref], [Google Scholar], [Publisher]

[22] I. Al-Qadsy, W.S. Saeed, A.A. Al-Owais, A. Semlali, A. Alrabie, L.A.S. Al-Faqeeh, M. ALSaeedy, A. Al-Adhreai, A.-B. Al-Odayni, M. Farooqui, Antimicrobial activity of novel Ni (II) and Zn (II) complexes with (*E*)-2-((5-bromothiazol-2-yl) imino) methyl) phenol ligand: Synthesis, characterization and molecular docking Studies, *Antibiotics*, **2023**, *12*, 1634. [Crossref], [Google Scholar], [Publisher]

[23] R. Shah, P.K. Verma, Therapeutic importance of synthetic thiophene, *Chemistry Central Journal*, **2018**, *12*, 1-22. [Crossref], [Google Scholar], [Publisher]

[24] G. Polinário, L.M.D.G. Primo, M.A.B.C. Rosa, F.H.M. Dett, P.A. Barbugli, C.A. Roque-Borda, F.R. Pavan, Antimicrobial peptides as drugs with double response against Mycobacterium tuberculosis coinfections in lung cancer, *Frontiers in Microbiology*, **2023**, *14*, 1183247. [Crossref], [Google Scholar], [Publisher]

[25] M. Kumar, T. Virmani, G. Kumar, R. Deshmukh, A. Sharma, S. Duarte, P. Brandão, P. Fonte, Nanocarriers in tuberculosis treatment: Challenges and delivery strategies, *Pharmaceuticals*, **2023**, *16*, 1360. [Crossref], [Google Scholar], [Publisher]

[26] Á. Mourenza, J.A. Gil, L.M. Mateos, M. Letek, Novel treatments against mycobacterium tuberculosis based on drug repurposing, *Antibiotics*, **2020**, *9*, 550. [Crossref], [Google Scholar], [Publisher]

[27] M. Kalumpha, L.C. Matsinha, B.C. Makhubela, Synthesis and characterization of Nickel (II) homogeneous and supported complexes for the hydrogenation of furfural to furfuryl alcohol, *Catalysts*, **2021**, *11*, 684. [Crossref], [Google Scholar], [Publisher]

[28] M. Bonnet, J.C. Lagier, D. Raoult, S. Khelaifia, Bacterial culture through selective and non-selective conditions: the evolution of culture media in clinical microbiology, *New Microbes and New Infections*, **2020**, *34*, 100622. [Crossref], [Google Scholar], [Publisher]

[29] M. Ghasemi, T. Turnbull, S. Sebastian, I. Kempson, The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis, *International Journal of Molecular Sciences*, **2021**, *22*, 12827. [Crossref], [Google Scholar], [Publisher]

[30] K. Matsuno, T. Saotome, N. Shimada, K. Nakamura, Y. Tabata, Effect of cell seeding methods on the distribution of cells into the gelatin hydrogel nonwoven fabric, *Regenerative Therapy*, **2020**, *14*, 160-164. [Crossref], [Google Scholar], [Publisher]

[31] S.R. Khan, Y. Manialawy, A.G. Siraki, Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action, *British Journal of Pharmacology*, **2019**, *176*, 4599-4608. [Crossref], [Google Scholar], [Publisher]

[32] S. Zeng, K. Soetaert, F. Ravon, M. Vandeput, D. Bald, J.-M. Kauffmann, V. Mathys, R. Wattiez, V. Fontaine, Isoniazid bactericidal activity involves electron transport chain perturbation, *Antimicrobial Agents and Chemotherapy*, **2019**, *63*, 10. [Crossref], [Google Scholar], [Publisher]

[33] L. Favrot, D.R. Ronning, Targeting the mycobacterial envelope for tuberculosis drug development, *Expert Review of Anti-Infective Therapy*, **2012**, *10*, 1023-1036. [Crossref], [Google Scholar], [Publisher]

[34] G.S. Timmins, S. Master, F. Rusnak, V. Deretic, Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against mycobacterium tuberculosis, *Antimicrobial Agents and Chemotherapy*, **2004**, *48*, 3006-3009. [Crossref], [Google Scholar], [Publisher]

[35] K.E. Dooley, S. Miyahara, F. von Groote-Bidlingmaier, X. Sun, R. Hafner, S.L. Rosenkranz, E.H. Ignatius, E.L. Nuermberger, L. Moran, K. Donahue, Early bactericidal activity of different isoniazid doses for drug-resistant tuberculosis (INHindsight): A randomized, open-label clinical trial, *American Journal of Respiratory and Critical Care Medicine*, **2020**, *201*, 1416-1424. [Crossref], [Google Scholar], [Publisher]

[36] A. Egorova, E.G. Salina, V. Makarov, Targeting non-replicating mycobacterium tuberculosis and latent infection: Alternatives and perspectives (mini-review), *International Journal of Molecular Sciences*, **2021**, *22*, 13317. [Crossref], [Google Scholar], [Publisher]

[37] S.L. Ngema, N. Dookie, R. Perumal, L. Nandlal, N. Naicker, M.P. Letsoalo, M. O'Donnell, A. Khan, N. Padayatchi, K. Naidoo, Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance, *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **2023**, *33*, 100387. [Crossref], [Google Scholar], [Publisher]

[38] B.W. Jhun, W.J. Koh, T.J. An, J.W. Kim, E.Y. Choi, S.H. Jang, H.Y. Lee, H.S. Kang, H.-K. Koo, J.M. Lee, Exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease: clinical implications of the use of inhaled corticosteroids, *Tuberculosis and Respiratory Diseases*, **2020**, *83*, 42-50. [Crossref], [Google Scholar], [Publisher]

[39] A. Quemard, C. LaCave, G. Laneelle, Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum, *Antimicrobial Agents and Chemotherapy*, **1991**, *35*, 1035-1039. [Crossref], [Google Scholar], [Publisher]

[40] I. Smith, Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence, *Clinical Microbiology Reviews*, **2003**, *16*, 463-496. [Crossref], [Google Scholar], [Publisher]

[41] C.E. Cade, A.C. Dlouhy, K.F. Medzihradszky, S.P. Salas-Castillo, R.A. Ghiladi, Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: Catalase, peroxidase, and INH-NADH adduct formation activities, *Protein Science*, **2010**, *19*, 458-474. [Crossref], [Google Scholar], [Publisher]

[42] C. Vilchèze, Mycobacterial cell wall: A source of successful targets for old and new drugs, *Applied Sciences*, **2020**, *10*, 2278. [Crossref], [Google Scholar], [Publisher]

[43] D.L. Campos, F.M. Demarqui, M.C. Solcia, P.C. de Souza, P.I. da Silva Maia, V.M. Deflon, F.R. Pavan, Latent tuberculosis: A promising new compound to treat non-replicating and intramacrophagic mycobacteria, *Biomedicines*, **2022**, *10*, 2398. [Crossref], [Google Scholar], [Publisher]

[44] V.A. Dartois, E.J. Rubin, Anti-tuberculosis treatment strategies and drug development: Challenges and priorities, *Nature Reviews Microbiology*, **2022**, *20*, 685-701. [Crossref], [Google Scholar], [Publisher]

[45] J.W.C. Alffenaar, J.E. de Steenwinkel, A.H. Diacon, U.S. Simonsson, S. Srivastava, S.G. Wicha, Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: an evaluation of in vitro, in vivo methodologies and human studies, *Frontiers in Pharmacology*, **2022**, *13*, 1063453. [Crossref], [Google Scholar], [Publisher]

HOW TO CITE THIS ARTICLE

A. R. Mohamed Sikkander, H. Yadav, Manoharan Meena. The Study Examined the Effectiveness of a Nickel (II) Complex Containing 5-Acetyl-*N*-(adamantan-2-yl) Thiophene-2-Carboxamide as a Derivative for the Drug Isoniazid in Relation to Bacterial, Cancer, and Tuberculosis Activities. *Adv. J. Chem. A*, 2024, 7(5), 501-521.

DOI: 10.48309/AJCA.2024.443156.1490
URL: https://www.ajchem-a.com/article_196535.html